Do emerging pharmacological therapies improve lipid control and cardiovascular outcomes in patients with hyperlipidemia and statin intolerance or suboptimal response?
Emerging pharmacological therapies offer new options for managing hyperlipidemia in patients who cannot tolerate or do not respond adequately to statins.
These therapeutic innovations represent a paradigm shift in hyperlipidemia management, providing mechanistically diverse and efficacious alternatives for patients with statin intolerance or suboptimal response to conventional therapies, ultimately enhancing lipid control and cardiovascular outcomes.
Sharma et al. (Thu,) studied this question.